Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07598838
Active, not recruiting Observational

Fitness in Elderly AML Patients

NCT07598838 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase
Observational
Started
2020-01-01
Last updated
2026-05-22

Condition(s) studied

AML (Acute Myelogenous Leukemia

Investigational drug(s) / intervention(s)

Fitness Categories: FIT, UNFIT and FRAIL

Fitness Categories: FIT, UNFIT and FRAIL: fitness categories and treatment received

Study summary

The study aims to evaluate the outcome of patients (overall survival) who received treatments commensurate with the proposed "Fitness" parameters compared to that of patients whose treatment differed either in the direction of greater or lesser aggressiveness than that proposed (evaluation of survival through Kaplan-Meier analysis and comparison with the log-rank test).

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Acute Myeloid Leukemia Diagnosis no Acute Promyelocytic Leukemia aged more than 65 years

Primary outcome measure(s)

  • overall survival according to fitness categories and treatment received — "From enrollment to the end of treatment at 12 months"

Trial sites (1)

FacilityCityRegionStatus
ASST Spedali Civili di Brescia Brescia Italy

More Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia trials in Italy

Bio-CAR-T BS Study Recruiting
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study Recruiting
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer Recruiting
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia Active, not recruiting
Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial Recruiting

Other trials for the same condition

Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07598838 on ClinicalTrials.gov ↗ ← All trials in Italy